Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...

Emboline expects that its technology designed to reduce stroke risk during structural heart procedures will launch in the US ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — In PROTECTED TAVR, the largest-ever randomized trial of transcatheter aortic valve replacement, ...

CHICAGO, IL—Cerebral embolic protection devices are infrequently used during transcatheter aortic valve implantation procedures in the United States, and new data suggest their use does not appear to ...

Emboline has secured $20 million for its embolic protection system, designed to minimize stroke risk associated with transcatheter aortic valve replacement procedures. The Santa Cruz, CA-based company ...

NEW YORK, NY—Use of a cerebral embolic protection device (EPD) during TAVI may prevent disabling strokes, but any effect appears to be modest, according to an updated analysis of the Society of ...

LONDON — Two years after the large multinational PROTECTED TAVR trial failed to associate a cerebral embolic protection (CEP) device with significant protection from stroke in patients undergoing ...

The Sentinel cerebral embolic protection (CEP) device failed to reduce the overall stroke rate in patients undergoing transcatheter aortic valve replacement (TAVR) in the largest TAVR trial to date, ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

The recall was initiated following reports of 9 device malfunctions. Cardiovascular Systems Inc. has issued a voluntary recall of unused WIRION ® Embolic Protection systems due to complaints of filter ...

(MENAFN- EIN Presswire) EINPresswire/ -- The Embolic Protection Devices Market is gaining significant traction globally, driven by the rising prevalence of cardiovascular diseases, increasing adoption ...